SEC Form 4 · accession 0001193125-26-383874
Kymera Therapeutics, Inc. · KYMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian Adams
Officer — Chief Legal Officer
Period of report
Sep 4, 2026
Accepted (ET)
Sep 4, 2026 · 6:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001815442
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 4, 2026 | S | 1,209 | $115.55 | D | 55,416 | D | |
| Common StockF3 | Sep 4, 2026 | S | 3,025 | $116.81 | D | 52,391 | D | |
| Common StockF4 | Sep 4, 2026 | S | 2,137 | $117.57 | D | 50,254 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $117.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.38 to $117.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.